Vaginal atrophy impacts women’s quality of life
Vaginal atrophy (VA) can have substantial effects on women’s quality of life and relationships, with about half of all postmenopausal women experiencing pain or discomfort from VA.1,2
There are many symptoms that can be caused by vaginal atrophy, with some of the most common including vaginal dryness, dyspareunia, itching, dysuria and burning.3
My Blissel® Time to talk
Video Library
A library of discussions led by national experts Dr Anne Connolly, Dr Diana Mansour and Nurse Specialist Consultant Nikki Noble.
The videos cover a range of very useful, relevant and important topics including, the signs and symptoms of VA, how to make the diagnosis and the impact of vaginal atrophy on a patient’s quality of life.
Why women need support and treatment
Women may find it difficult to talk about vaginal atrophy, and they may want their doctor to start the discussion.4
There are various reasons why women may not feel able to discuss VA with their doctor.5
These can include embarrassment, incorrectly believing that there is no available treatment, or thinking that talking about their symptoms is not appropriate.5
Guidance states that treatment using vaginal oestrogen should be offered for the symptoms of vaginal atrophy.6
Even with clear guidelines, about 50% of all women who have genitourinary symptoms after the menopause have never been prescribed a solution for their symptoms.7
Using Blissel® to treat vaginal atrophy
Blissel® is an ultra low dose estriol vaginal gel containing 50 micrograms per dose (1 gram) of estriol, which is indicated for treating the symptoms of vaginal atrophy due to oestrogen deficiency in postmenopausal women.8,9
The treatment is well tolerated and effective for postmenopausal vaginal atrophy.8 Your patients may notice a rapid improvement in their symptoms from the initial days of treatment when you prescribe Blissel®.10
Prescribe Blissel® by brand for your patients. Blissel®is the first and only prescribable estriol containing gel for the treatment of vaginal atrophy8,9
Guidelines on the treatment of vaginal atrophy
NICE guidelines provide clear direction that local therapy is preferable to systemic treatment for vaginal symptoms.6 Guidelines advocate to provide vaginal oestrogen to women to manage bothersome symptoms of vaginal atrophy.6
Despite clear guidelines, half of all women who experience genitourinary symptoms after the menopause have not received any treatment at all for their symptoms.7
Treating vaginal atrophy with Blissel®
Blissel® is an ultra low dose estriol vaginal gel containing 50 micrograms per dose (1 gram) of estriol, indicated for treating the symptoms of vaginal atrophy due to oestrogen deficiency in postmenopausal women.8,9
For postmenopausal vaginal atrophy, the treatment has been shown to be well-tolerated and effective.8 Blissel® gives your patients a rapid improvement in their symptoms from the first days of treatment.10
Upcoming Webinars 2025
4th Feb
7pm to
9pm
Balancing Act: Hormone replacement therapy HRT in Genitourinary health with Dr Diana Mansour.
- Looking for more information on understanding Menopause and Genitourinary symptoms?
- For more information please click below
How BlisselⓇ
Works
Efficacy
Dosing
Ultra low dose estriol vaginal gel8,9
Prescribing and Adverse event reporting information for BlisselⓇ can be found here.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Consilient Health (UK) Ltd, No. 1 Church Road, Richmond upon Thames, Surrey TW9 2QE UK or drugsafety@consilienthealth.com
1. Nappi RE, Palacios S. Climacteric. 2014;17:3–9. 2. Moral E, et al. Menopause. 2018;25(12):1418-23.
3. Palmaa F, et al. Maturitas. 2018;108:18–23. 4. Krychman M, et al. J Sex Med 2017;14:425-433.
5. Kagan R, et al. Drugs Aging. 2019;36:897–908. 6. NICE. Menopause: diagnosis and management (NG23). Available from: https://
www.nice.org.uk/guidance/ng23/chapter/recommendations. Accessed December 2023.
7. NAMS position statement. Menopause. 2020;27(9):976-92. 8. Cano A, et al. Menopause. 2012;19(10):1130-9.
9. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics.
10. Lázaro-Carrasco de la Fuente J, et al. J Menopausal Med. 2022;28(2):60-69.
Date of preparation: Jan 2025 | UK-BLS-611